Faculty Disclosure In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. If an individual refuses to disclose relevant financial relationships, they will be disqualified from being a part of the planning and implementation of this CME activity. Owners and/or employees of a commercial interest with business lines or products relating to the content of the CME activity will not be permitted to participate in the planning or execution of any accredited activity. Nature of Relevant Financial Relationship Last Name Commercial Interest What Was Received For What Role Ali None N/A N/A Andrey None N/A N/A Bauml Clovis, Bristol‐Myers Squibb, Astra Zeneca, Celgene, Boehringer Honorarium Consultant Ingleheim, Merck, Guardant Health, Genentech Sciences Merck, Clovis, Carevive Systems, Novartis, Bayer Pharmaceutics Research Support Principal Investigator company Birchard None N/A N/A Bollin None N/A N/A Botta None N/A N/A Costantini None N/A N/A Durand None N/A N/A El‐Khoueiry None N/A N/A Eng Bayer Healthcare, Sirtex Honorarium Consultant Genentech, Roche, Bayer Healthcare Honorarium Speaker Daiichi pharmaceutical Keryx Grant Research Support Garcia Daiichi Sankyo Company, Ltd., Bayer Pharmaceutics company, Research Support Principal Investigator Janssen Pharmaceuticals, Inc. Gertz Alnylam, Prothena Corp Honorarium Consultant Ionis, WebMD, Physicians Education Resource, Amgen, Pharmacyclics, Honorarium Speaker Janssen Janssen, Celgene Honorarium Advisory Board Appellees Honorarium Research Grubbs None N/A N/A Hassell Pfizer Inc. Honorarium Steering Committee Horn Bristol‐Myers Squibb, Lilly, AstraZeneca, AbbVie, Merck, Honorarium Advisory Board Genentech Sciences BMS, Lilly, AZ, AbbVie, Merck, Honorarium Consultant Genentech, Xcovery, Bayer, Janssen Hudson None N/A N/A Hurvitz Lilly, Novartis, OBI Pharma, Bayer Honorarium Speaker Amgen, Bayer Pharmaceutics company,Boehringer Ingelheim, Genentech Sciences, GlaxoSmithKline,Eli Lilly, Novartis, Pfixer, Roche, PUMA, Merrimack, Grant Research Medication, Dignitana, OBI Pharma, Inc., BioMarin Pharmaceutical, Cascadian Therapeutics Seattle Genetics Kantarjian Amgen, ARIAD Pharmaceuticals, Astec, Inc, Bristol‐Myers Squibb, Grants Research Norvartis, Pfizer AbbVie, Amgen, ARIAD Pharmaceuticals, Bristol‐Myers Honorarium Consultant Squibb, Orsenex, Pfizer, ImmunoGen Kelton None N/A N/A Kim AstraZeneca, Celgene, Eli Lilly, Research Grant/ Consultant Boehringer Ingelheim Honorarium Kitchens None N/A N/A Kosty EMD Serono, Merck, Genentech Grants Research Support Sciences, Amgen Biocept Consulting Fees Consultant Mahindra Amgen Honorarium Advisory Board Sanofi Aventis Honorarium Speaker Celgene; Millennium Grants Research Funding pharmaceuticals Malekirad None N/A N/A Mason Gilead Sciences Honorarium Speaker McAneny None N/A N/A McArthur Amgen , Celgene , Merck , OBI Pharma, Inc, Spectrum Pharmaceuticals, Syndax Honorarium Consultant/Advisory Pharmaceuticals, Roche, Peregrine, Board Calithera, TapImmune Bristol‐Myers Squibb, Eli Lilly , Honorarium Research MedImmune, AstraZeneca , Merck Moll None N/A N/A O'Shaughnessy AstraZeneca, Pfizer, Eli Lilly, Novartis Will disclose on‐site Will disclose on‐site Quinn None N/A N/A Reeves None N/A N/A Saven Celgene Corporation, Gilead Sciences,Incyte, Millennium Pharmaceuticals,Inc., Onyx Honorarium Speakers Bureau Pharmaceuticals, Inc., Pharmacyclics, Seattle Genetics Schuster •Seattle Genetics, Janssen, Novartis, Research support, Merck, Genentech Sciences , Nordic Honorarium consultant, Advisory board Nanovecto Gilead Sciences Honorarium Consultant, Advisory board Research support, Celgene, Pharmacyclics Honorarium consultant, advisory board, steering committee Stover None N/A N/A Tarhini Celgene Corporation, Gilead Sciences Inc., Incyte Corporation, Seattle Honorarium Speaker/Advisor Genetics Bristol‐Myers Squibb, Merck, Amgen, Grant Research Prometheus, Incyt Torrey None N/A N/A Wang Abbvie, Arog Pharmaceuticals, Honorarium Advisory board Celgene, Agios, Pfizer, Takeda Incyte Corporation, Novartis, Jazz Honorarium Speaker Pharmaceuticals Immunogen Honorarium Advisory Board, Research Warkentin Aspen Global Bayer , WL Gore, Law firm, Instrumentation Laboratory, Honorarium Consultant Octapharma Xavier Celgene Corporation, Gilead Sciences Inc., Incyte Corporation, Seattle Honorarium Speaker/Advisor Genetics CME Review None N/A N/A Committee Peer Reviewer Botta None N/A N/A Peer Reviewer None N/A N/A Malekirad Scripps Conference None N/A N/A Services & CME Glossary of Terms Commercial Interest The ACCME defines a “commercial interest” as any entity producing, marketing, re‐selling, or distributing health care goods or services, used on, or consumed by, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. Financial Relationships Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner. Relevant Financial Relationships ACCME focuses on financial relationships with commercial interests in the 12‐month period preceding the time that the individual is being asked to assume a role controlling content of the CME activity. ACCME has not set a minimal dollar amount for relationships to be significant. Inherent iny an amount is the incentive to maintain or increase the value of the relationship. The ACCME defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Conflict of Interest Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of a commercial interest with which he/she has a financial relationship. .